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Neuroendocrine differentiation in prostatic carcinomas generally confers a more aggressive clinical behavior and less favorable
prognosis than usual prostatic carcinomas. In this manuscript, we report a case of a 58-year-old man with prostatic carcinoma who
died 1 year after initial diagnosis. Autopsy showed a disseminated prostatic carcinoma with neuroendocrine differentiation. There
were metastasis to the spleen, an organ infrequently involved by disseminated epithelial neoplasms. Neuroendocrine differentiation
was demonstrated by immunohistochemical studies in the biopsy and autopsy material.
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metastasis.
Prostate carcinomas usually occur af-
ter the age of 50, with a higher incidence
after the age of 701. They are the most
common neoplasia in men and the sec-
ond highest cause of death by cancer in
the United States, second only to lung
cancer2. The death rate resulting from
prostate carcinoma has been growing in
Brazil, with an estimated 14800 new
cases and 6850 deaths for the year 20003.
About 95% of the malignant pros-
tatic neoplasms are adenocarcinomas2.
Neuroendocrine cells are abundant in
the prostate and are diffusely distrib-
uted throughout the organ at birth4,5.
According to the literature, depending
on the sensitivity of the technique ap-
plied, traces of neuroendocrine differ-
entiation can be found in the adenocar-
cinomas in 10% to 100% of the cases6.
The cases of malignant neoplasia of
the prostate with neuroendocrine dif-
ferentiation have poorer prognosis
(35% survival rate in 2 years) than
cases without it (97% survival rate in
2 years)7,8.
In the following report, we describe
a case of a patient having prostatic ad-
enocarcinoma with extensive neuroen-
docrine differentiation and rapid evo-
lution to death (12 months after diag-
nosis); the autopsy revealed extensive
dissemination of the neoplasia.
CASE REPORT
A white male patient, 58 years old, was
admitted to another medical service in
January 1998 complaining of a decrease in
urinary flow rate and an acute episode of
urinary retention. There he underwent tran-
surethral resection (TUR) in March 1998
for de-obstruction of the excretory tract. A
prostate adenocarcinoma with PSA serum
values of 33 ng/ml was discovered from
this procedure. In May of the same year,
the patient was admitted to this service and
underwent an ultrasound examination,
which revealed a prostate measuring 4.7 x
4.1 x 3.8 cm with an estimated weight of
40 g. The patient complained of pelvic and
lumbar pain. Bone scintillography in June
1998 showed alterations suggesting a sec-
ondary compromise by the neoplasia of the
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sternocostal articulation, sternum, vertebral
bodies (C1-C2; T4-T5; L2; L5-S1), 1st
right-anterior costal arc, 3rd, 4th, 7th and 9th
right-posterior costal arcs, 3rd and 8th left-
posterior costal arcs, left sacroiliac liga-
ment, bilateral ischia, and proximal third of
the femur. A bilateral subcapsular orchiec-
tomy was executed (July 1998) with ana-
tomic-pathologic results of “testicles within
normal limits for age”. In November of the
same year, a new palliative TUR (15 g) was
executed revealing “prostate carcinoma
with a Gleason score of 10 (5 + 5) in 100%
of the fragments, and presence of perineu-
ral invasiveness.” Two days after the surgi-
cal procedure, the patient presented hema-
turia, tachycardia, and postural hypoten-
sion, and underwent hemostasia of the
bleeding vessels of the prostatic compart-
ment and a transfusion of erythrocyte con-
centrate. Beyond this date, the patient
evolved into generalized weakness and
chronic anemia, and was sent twice to the
emergency room to receive erythrocyte
concentrate and support therapy. At the end
of February 1999, the patient came once
more to our hospital with paleness and sig-
nificant pancytopenia, developed a new
episode of hematuria, experienced a low-
ering of the consciousness level, and died
on March 1, 1999.
An autopsy was indicated to identify
the level of dissemination of the neopla-
sia. During necropsy, extreme cachexia
was externally evident. The prostate was
enlarged, with the neoplasia measuring
6 cm on its largest axis, hardened, whit-
ish, showing a large central necrotic
area, infiltrating the rectum and bladder.
In the thoracic cavity, bilateral serous
effusion was found with multiple
paraortic and parietal pleura metastases.
The lungs had multiple tumor masses—
the largest measuring 2.5 cm—close to
the pleural surface. A number of hilar
lymph nodes were macroscopically
found to be compromised by the neo-
plasia. In the abdominal cavity, no free
fluids were seen, and the liver, spleen,
and adrenal glands had metastases mea-
suring between 5 and 2 cm.
At microscopy of the primary pro-
static tumor, poorly differentiated ad-
enocarcinoma was seen, which was
characterized by solid cell proliferation
with intense pleomorphism and plump
nuclei showing intense hyperchromasia
and many mitotic figures (Fig. 1). In
the metastases, the tumor had a solid
trabecular displacement, with nuclear
molding resembling that of neuroendo-
crine neoplasia (Figs. 2 and 3).
The immunohistochemical panel was
done for the primary prostatic tumor and
the metastases, revealing both to be dif-
fusely positive for prostatic specific an-
tigen (PSA) (DAKO M0750, Glostrup,
Denmark) and neuron-specific enolase
(NSE) (DAKO M0873, Glostrup, Den-
mark), focally positive for chromogranin
A (DAKO M0869, Glostrup, Denmark)
and negative for synaptophysin (DAKO
M0776, Glostrup, Denmark). The tumor
marker panel was applied retrospectively
to the histologically prepared material
obtained with the last TUR, producing
results similar to those of the autopsy
(Figs. 4 and 5).
DISCUSSION
The current report describes a case
of prostatic carcinoma that had an ex-
tremely aggressive biological behavior.
Figure 1 - Poorly differentiated prostatic adenocarcinoma (hematoxylin – eosin; 100x).
Figure 2 - Liver metastasis. Solid tumor with trabecular displacement. The neoplasia compresses
permeating hepatocellular chain (arrow) (hematoxylin – eosin; 100x).
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Only 1 year elapsed between the initial
diagnosis and the patient’s death with
disseminated neoplasia. The histopatho-
logical examination revealed a poorly
differentiated carcinoma with extensive
neuroendocrine differentiation, as deter-
mined from immunohistochemical ex-
amination. Cases of malignant neopla-
sia of the prostate with neuroendocrine
differentiation have a poorer prognosis
(35% survival rate in 2 years) than cases
without neuroendocrine differentiation
(97% survival rate in 2 years)7,8, in ad-
dition to being associated with an inde-
pendent androgen state.
The cells of the diffuse neuroendo-
crine system (formerly known as the
APUD system) are located centrally in
the human body (hypophysis, hypo-
thalamus, and pineal) and peripherally
(lung, gastrointestinal tract, thyroid,
ducts, and epithelium of the prostatic
acini among other organs)6. It is gen-
erally believed that in the prostate,
these cells are involved in regulation of
growth and development of the organ,
as well as regulation of the secretory
processes of the mature gland6. Pros-
tatic carcinoma can present diverging
differentiation of neuroendocrine phe-
notypes in the form of small cell neu-
roendocrine carcinoma (rare variant,
encompassing 5% to 2% of all pros-
tatic carcinomas)9 or of carcinoid-like
tumors. It is also believed that pure
prostatic neuroendocrine neoplasia de-
rives from multipotent stem cells mani-
fested in the organ10. Much more com-
mon is the focal neuroendocrine differ-
entiation in prostatic adenocarcinomas,
which can be more exuberant in 10%
of the adenocarcinomas11. According to
the literature, depending on the method
used, from 10% to 100% of the pros-
tate carcinomas present clusters of neu-
roendocrine differentiation6. More
rarely, two different forms of neuroen-
docrine differentiation can occur in the
same patient with prostate neoplasia12.
The degree of neuroendocrine dif-
ferentiation in a conventional adeno-
Figure 4 - Immunohistochemical examination using anti-chromogranin A antibody demonstrating
focal positivity of neuroendocrine cells in the prostate (100x).
Figure 3 - Detail of the previous picture. Note the intense occurrence of atypical cells, mitoses and
certain degree of nuclear molding (hematoxylin – eosin; 200x).
Figure 5 - Immunohistochemical examination in the liver metastasis showing intense positivity of
neoplastic cells for anti-chromogranin A antibody (100x).
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carcinoma seems to be directly related
to the degree of aggressiveness of the
tumor6. It is still not clear if the aggres-
sive behavior is a reflection of the neu-
roendocrine differentiation or merely
due to a high tumor level. It is not un-
common to observe the progression of
a typical prostate adenocarcinoma with
minimal or no neuroendocrine differ-
entiation to a neuroendocrine carci-
noma or a carcinoma with neuroendo-
crine differentiation that is unrespon-
sive to hormone therapy6.
Although still not well defined, the
reasons that might cause the poor prog-
nosis of this histologic subtype may in-
clude active neuroendocrine cell prod-
ucts, such as a growth factor, and the
lack of androgen receptors in the neu-
roendocrine cells13, which would also
account for unresponsiveness to hor-
monal treatment. Wu et al. studied 14
cases of prostatic carcinomas that were
resistant to hormonal treatment. High
serum values of chromogranin A were
noticed in 10 cases, while PSA re-
mained at normal levels, and NSE was
not detected. The early detection of
high serum levels of chromogranin A
could be an indicator for a change to a
more aggressive therapy14. Jiborn et al.
suggested that androgen ablation
therapy might increase the selection
and progression of neoplastic neuroen-
docrine cells15. Diaz et al. investigated
the effects of the interleukins (IL)-1ß,
-2 and -6 in the chromogranin A ex-
pression, demonstrating that IL-1ß and
IL-6 increase the secretion of
chromogranin A in LNCaP and DU-
145 cells (prostate cancer cell lines)
while IL-2 decreases chromogranin A
secretion. These results suggest the
cytokines IL-1ß and IL-6 can influence
the neuroendocrine differentiation in
prostate carcinoma and could be
involved in the progression of the
disease16.
Immunohistochemical examination
of the neoplastic tissue is fundamental
for the correct diagnosis of this histo-
logic subtype of prostatic neoplasia, al-
lowing for a number of neuroendocrine
tumor markers to be used, such as in the
presented case. Anti-NSE reacts with
the gamma-gamma isoform of the eno-
lase, which is commonly used as a neu-
roendocrine marker17. Its positivity is
not totally specific, with reports of
marking by anti-NSE of non-neuroen-
docrine tissues18. Chromogranin A,
which is a component protein of the
secretory granules of endocrine cells
and neurons17, is much more specific
than NSE. Even when all cells are not
marked with its antibody, its positivity
in neoplastic cells indicates neuroendo-
crine differentiation of an adenocarci-
noma18. Chromogranin A seems to be
the best marker of blood and tissue neu-
roendocrine differentiation, with its se-
rum value being used to show appear-
ance or progression of hormone-therapy
resistance in prostate carcinomas11.
Synaptophysin, a calcium-binding pro-
tein, is present in the pre-synaptic
vesicles of the neuron and in the neu-
rosecretory granules of the neuroendo-
crine cells. Although synaptophysin is
a marker for neuroendocrine differentia-
tion, there is difficulty in the usage of
its antibody, because the reactions are
difficult to interpret due to its frequently
meager intensity and constant back-
ground staining17. PSA (antigen of the
normal prostate epithelium and its car-
cinomas)17, is a reliable marker in the
identification of the prostate as a pri-
mary neoplastic site. Another prostate
cancer marker, prostatic acid phos-
phatase (enzyme secreted by the pros-
tate epithelium and present in semen as
well as blood)17 can cross-react with
lung and gastrointestinal carcinoid tu-
mors, mainly in rectal carcinoids. In
cases of small cell carcinoma of the
prostate without an associated adenocar-
cinoma element, the anti-PSA test can
be negative19.
There is still no effective treatment
for malignant neoplasia of the prostate
with neuroendocrine differentiation.
Conventional chemotherapy directed
against small cell lung tumors has been
used in some cases20,21. Potential thera-
pies directed toward neuroendocrine
hormones and/or their antagonists, such
as somatostatin, bombesin, and seroto-
nin, have been receiving attention22.
In our presented case, a higher ag-
gressiveness was confirmed not only
through rapid evolution to death (1
year), but also through the extent of the
metastases afflicting organs such as the
spleen, which is less commonly stricken
by neoplasias originating in the epithe-
lium. The incidence of metastases of
solid tumors in the spleen ranges from
1.6% to 30% in autopsy studies23. In a
study conducted on 20 cases of small
cell carcinoma of the prostate, there
were no metastases to the spleen in any
of them20. Our case has drawn our at-
tention to the fact that evidence of neu-
roendocrine differentiation in prostate
neoplasias should be always thoroughly
researched through precise histopatho-
logical examination. It is not reasonable
to propose that an immunohistochemi-
cal panel, such as the one used in our
case, be incorporated to routine diagno-
sis for all prostate tumors; however, it
should be applied in cases in which
morphology indicates its need.
In cases of unusual prostatic neo-
plasias with uncertain prognosis, biopsy
and histological diagnosis are essential,
since the role of imaging is restricted to
local and metastatic evaluation of the dis-
ease24. In this scenario, the importance of
the pathologist is enhanced; the patholo-
gist can assist in establishing the prog-
nosis and orienting precocious treatment
based on more rational grounds.
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neoplasias prostáticas usuais. No pre-
sente relato de caso é reportada a rápi-
da evolução para o óbito de um paci-
ente de 58 anos portador de adenocar-
cinoma de próstata com diferenciação
neuroendócrina. A autópsia mostrou
neoplasia disseminada, acometendo in-
clusive o baço, sítio incomum de en-
volvimento metastático de neoplasias
de origem epitelial. A diferenciação
neuroendócrina foi demonstrada por
estudo imunohistoquímico em materi-
al de biópsia e autópsia.
DESCRITORES: Carcinoma de
próstata. Diferenciação neuro-
endócrina. Autópsia. Imunohisto-
química. Metástase esplênica.
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Os carcinomas da próstata com di-
ferenciação neuroendócrina apresen-
tam comportamento mais agressivo e
prognóstico menos favorável que as
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